Search results
Showing 331 to 345 of 703 results for end of life care
Autism spectrum disorder in under 19s: recognition, referral and diagnosis (CG128)
This guideline covers recognising and diagnosing autism spectrum disorder in children and young people from birth up to 19 years. It also covers referral. It aims to improve the experience of children, young people and those who care for them.
Selective internal radiation therapies for treating hepatocellular carcinoma (TA688)
Evidence-based recommendations on selective internal radiation therapies SIR-Spheres (Sirtex), TheraSphere (BTG) and QuiremSphere (Quirem Medical) for treating hepatocellular carcinoma in adults.
Relugolix–estradiol–norethisterone for treating symptoms of endometriosis (TA1057)
Evidence-based recommendations on relugolix–estradiol–norethisterone (Ryeqo) for treating symptoms of endometriosis in adults of reproductive age.
Show all sections
This guideline covers managing and monitoring diabetic retinopathy in people under the care of hospital eye services. This includes non-proliferative and proliferative diabetic retinopathy, and diabetic macular oedema.
NG61/2 Question Perinatal palliative care:- What impact does timely perinatal palliative care have on the experience of...
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults.
Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)
Evidence-based recommendations on tildrakizumab (Ilumetri) for treating moderate to severe plaque psoriasis in adults.
Evidence-based recommendations on apremilast (Otezla) for treating active psoriatic arthritis.
Padeliporfin for untreated localised prostate cancer (TA546)
Evidence-based recommendations on padeliporfin (Tookad) for untreated, unilateral, low-risk prostate cancer in adults.
Evidence-based recommendations on colistimethate sodium (Colobreathe) and tobramycin (TOBI Podhaler) dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis in people of 6 years and over.
Omalizumab for previously treated chronic spontaneous urticaria (TA339)
Evidence-based recommendations on omalizumab (Xolair) for treating severe chronic spontaneous urticaria in people of 12 and over.
Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.
dying:- What signs and symptoms indicate that a child or young person with a life-limiting condition is likely to die within hours or...
Evidence-based recommendations on dabrafenib (Tafinlar) with trametinib (Mekinist) for resected stage III, BRAF V600 mutation-positive melanoma in adults.
Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)
Evidence-based recommendations on mannitol dry powder for inhalation (Bronchitol) for treating cystic fibrosis in adults